On Monday, H.C. Wainwright adjusted its stock price target for Tyra Biosciences (NASDAQ:TYRA), a company specializing in precision medicine oncology drugs. The firm reduced the price target to $30 from $32 while maintaining a Buy rating on the stock. This adjustment follows a review of recent clinical data and the potential of Tyra's lead compound, TYRA-300, particularly in its application to non-muscle-invasive bladder cancer (NMIBC).
The analyst at H.C. Wainwright cited recent Phase 1/2 data for TYRA-300 in metastatic urothelial carcinoma (mUC) as a basis for continued optimism. In the mUC study, the drug demonstrated a 55% partial response rate and a 27% near partial response rate at the dose range of ≥90mg. All patients receiving doses at this level experienced tumor regression, indicating a therapeutic benefit. The safety profile of TYRA-300 was also highlighted as encouraging, showing fewer specific toxicities compared to Johnson & Johnson's Balversa (erdafitinib) at comparable doses.
Furthermore, the analyst noted that at doses of ≥60mg, there were no discontinuations or dose reductions, and any adverse events were Grade 1-2, which are considered mild. This included a single case of elevated alanine aminotransferase (ALT), a liver enzyme, deemed inconsequential.
Comparing the efficacy of TYRA-300 to Johnson & Johnson's Balversa in NMIBC, the analyst pointed to the lower dose level's success in a separate NMIBC study, suggesting potential efficacy at lower dosages.
Looking ahead, Tyra Biosciences is set to continue optimizing dosing in mUC before proceeding to a larger Phase 2 study. Moreover, the company plans to submit an Investigational New Drug (IND) application to commence a Phase 2 trial in NMIBC and initiate a Phase 2 study in achondroplasia (ACH), with dosing expected to begin in the first quarter of 2025.
The reduction in Tyra Biosciences' price target reflects a cautious but optimistic outlook for TYRA-300's future, with the analyst reiterating the Buy rating and adjusting the price target slightly to account for recent data and anticipated developments in the drug's clinical journey.
In other recent news, Tyra Biosciences has made substantial strides in its clinical trials and financial prospects. The FDA approved the company's Phase 2 trial for its drug TYRA-300, aimed at treating achondroplasia. This trial, named BEACH301, will assess the drug's safety and its impact on annualized growth velocity.
Piper Sandler has maintained an Overweight rating on Tyra Biosciences, following the FDA's clearance, and reaffirmed a steady price target of $33.00. Furthermore, H.C. Wainwright has lifted its stock target for Tyra Biosciences, retaining a Buy rating, following encouraging data from the SURF-301 Phase 1/2 trial of TYRA-300 in metastatic urothelial carcinoma.
TD Cowen also maintained a Buy rating on the company's shares after positive preliminary results from the Triple abstract. These recent developments indicate a positive progression in the company's development pipeline.
